NCT06305702Completed
Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
Multicenter Real-world Clinical Study of Inetetamab-based Therapy in HER2-positive Metastatic Breast Cancer
Source: ClinicalTrials.gov · Last updated 12 Mar 2024
Brief summary (registry, in English)
A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 500 (actual)
- First submitted
- 5 Mar 2024
- Start date
- 1 Jul 2022
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Liaoning Cancer Hospital & Institute
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06305702
What you commit to
- Study type: Observational
- Participants enrolled: 500
- From 1 Jul 2022 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other conditions deemed unsuitable for participating in this study by the researcher
Other
- Pregnant or lactating women
Who the study is looking for
- An age of at least 18 years or older
- Pathologically diagnosed with HER2-positive recurrent or metastatic breast cancer
- Having at least one measurable lesion as defined
- Receiving inetetamab-based therapy in the recurrent or metastatic stage
- Having traceable medical history records
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Liaoning Cancer Hospital &Institue Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.